Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-871-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
OptionableOptionable
Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions
What is Eleven Biotherapeutics' stock symbol?
Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."
How were Eleven Biotherapeutics' earnings last quarter?
Eleven Biotherapeutics (NASDAQ:EBIO) posted its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.
What price target have analysts set for EBIO?
2 brokers have issued 12-month price objectives for Eleven Biotherapeutics' shares. Their forecasts range from $2.00 to $8.00. On average, they expect Eleven Biotherapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Price Targets for Eleven Biotherapeutics.
What is the consensus analysts' recommendation for Eleven Biotherapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eleven Biotherapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eleven Biotherapeutics.
Has Eleven Biotherapeutics been receiving favorable news coverage?
News stories about EBIO stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eleven Biotherapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the near future.
Who are some of Eleven Biotherapeutics' key competitors?
Some companies that are related to Eleven Biotherapeutics include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Egalet (EGLT).
Who are Eleven Biotherapeutics' key executives?
Eleven Biotherapeutics' management team includes the folowing people:
- Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
- Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
- Dr. Gregory L. Verdine, Co-Founder (Age 59)
- Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
- Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board
How do I buy shares of Eleven Biotherapeutics?
Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eleven Biotherapeutics' official website?
How can I contact Eleven Biotherapeutics?
Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]
MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
